An interventional study of Topical skin soothing essence 1.0 and Topical skin soothing essence 2.0 in Mildly Sensitive Skin, sponsored by ChinaNorm. Completed at 1 site in China. Open to female participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by ChinaNorm · Not applicable, Interventional, and Other
The goal of this study is to explore the soothing effect of two test products within two hours after a single use by analyzing the changes in various indicators including clinical evaluation, non-invasive instrument measurement, image analysis and participant self-evaluation before and after product application.
The main questions it aims to answer are:
Can the two test products effectively relieve skin discomfort within two hours after a single use? What changes do multiple skin indicators show at different time points after the single application of the two test products? Researchers will adopt a single-center, split-face controlled study design. A total of about 124 healthy Chinese women aged 20-40 years will be enrolled and randomly divided into 2 groups with approximately 62 participants in each group.
Participants will:
Receive a single application of the assigned test product; Undergo skin indicator detection and clinical evaluation at scheduled time points within two hours after product application; Complete relevant self-evaluation questionnaires to record skin subjective feelings.
ChinaNorm is the lead sponsor of 28 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Female Chinese subjects, aged 20-40 years old; 2. All skin types, with self-reported mild sensitive skin; 3. Self-reported tendency of easy skin flushing and erythema; 4. Full-face assessment by a dermatologist confirming the following skin characteristic:
Exclusion Criteria:
Single topical application of Test Essence 1.0 on one side of the subject's face.
Other: Topical skin soothing essence 1.0
Single topical application of Test Essence 2.0 on one side of the subject's face.
Other: Topical skin soothing essence 2.0
Topical skin soothing essence 1.0, applied once to one side of the subject's face in this split-face study, to evaluate its soothing effect on induced skin redness.
Topical skin soothing essence 2.0, applied once to one side of the subject's face in this split-face study, to evaluate its soothing effect on induced skin redness.
Change in skin erythema measured by Mexameter® MX18
Skin erythema is measured by Mexameter® MX18 at baseline (BL). Compare the change of skin a\* value between the side applied with Test Essence 1.0 and the side applied with Test Essence 2.0 in this split-face study, to evaluate the skin soothing effect on infrared-induced skin redness.
Time frame: Baseline , post-induction (T0), 10 minutes, 1 hour and 2 hours after product application
Clinical skin redness score assessed by dermatologist
Dermatologist assesses skin redness using modified Griffiths 10-point scale (0.5 increments allowed) at Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application. The same dermatologist evaluates the same subject and is blinded to prior scores. Compare score changes between two sides of face.
Time frame: Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application
Proportion of red area from VISIA 7 facial image analysis
Facial images are captured by VISIA7 under standard, cross-polarized and UV light. IPP software is used to analyze red area proportion at Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application. Compare red area proportion changes between two facial sides.
Time frame: Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application
TiVi index (red blood cell concentration) measured by TiVi700
TiVi700 is used to detect red blood cell concentration (TiVi index) of bilateral cheeks at Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application. Compare TiVi index changes between two sides.
Time frame: Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application
Skin temperature measured by FLUKE TIS60+ infrared camera
Facial skin temperature is acquired by FLUKE TIS60+ infrared camera at Baseline , post-induction , 5 minutes,10 minutes, 1 hour and 2 hours after product application. Compare skin temperature changes between two facial sides.
Time frame: Baseline , post-induction , 5 minutes,10 minutes, 1 hour and 2 hours after product application
Subject self-assessment score of skin discomfort (0-4 scale)
Subjects complete self-assessment questionnaire for stinging, itching, burning and tightness (0-4 scale) at Post-induction , 10 minutes, 1 hour and 2 hours after product application. Higher scores mean more severe discomfort.
Time frame: Post-induction , 10 minutes, 1 hour and 2 hours after product application
Subject questionnaire on product sensory experience
Subjects complete self-reported questionnaire regarding skin condition after product use at 10 minutes, 1 hour and 2 hours after product application.
Time frame: 10 minutes, 1 hour and 2 hours after product application
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.